Immunome, Inc.
IMNM
$15.67
-$0.82-4.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 37.22% | 6.87% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 37.22% | 6.87% | |||
| Cost of Revenue | -93.94% | -23.01% | |||
| Gross Profit | 105.25% | 24.82% | |||
| SG&A Expenses | -6.06% | 2.34% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.16% | -18.47% | |||
| Operating Income | -4.13% | 19.72% | |||
| Income Before Tax | -4.22% | 48.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4.22% | 48.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.22% | 48.11% | |||
| EBIT | -4.13% | 19.72% | |||
| EBITDA | -4.12% | 20.17% | |||
| EPS Basic | 4.88% | 58.94% | |||
| Normalized Basic EPS | 4.88% | 37.69% | |||
| EPS Diluted | 4.88% | 59.06% | |||
| Normalized Diluted EPS | 4.88% | 37.69% | |||
| Average Basic Shares Outstanding | 9.57% | 26.37% | |||
| Average Diluted Shares Outstanding | 9.57% | 26.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||